ProPublica: Safety questions over GSK’s Advair linger after years on the asthma throne

Carly Helfand

U.S. regulators gave GlaxoSmithKline's the green light a decade and a half ago, paving the way for a long reign that saw the med grow to more than $ 8 billion in annual sales. But even all these years, whether Advair poses a higher risk of -related death remains unclear, says.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS